Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASFRA:PI3 +4.38%75 3-Year EBITDA Growth Rate is 428.40% as of Dec. 2025, which is at its 10-year median of 428.40. GuruFocus rates FRA:PI3 with a GF Score™ of 75/100 and a GF Value™ of €386.89 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, Gubra AS ranks better than 99.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 428.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gubra AS was 428.40% per year. The lowest was 428.40% per year. And the median was 428.40% per year.
Gubra AS (FRA:PI3) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gubra AS 3-Year EBITDA Growth Rate Related Terms
FRA:PI3 vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Gubra AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gubra AS's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 428.40% mean?
Gubra AS (FRA:PI3) has a 3-Year EBITDA Growth Rate of 428.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gubra AS and its competitors. This is near median its historical median of 428.40. Over the past decade, Gubra AS's 3-Year EBITDA Growth Rate has ranged from 428.40 to 428.40. According to the industry distribution chart, Gubra AS ranks #2 out of 1136 companies in the Biotechnology industry, placing it in the top 0.2%.
Is Gubra AS's 3-Year EBITDA Growth Rate too high?
Gubra AS's current 3-Year EBITDA Growth Rate of 428.40% is near median its 10-year median of 428.40. Over the past 10 years, this metric has ranged from a low of 428.40 to a high of 428.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Gubra AS's value of 428.40% is 2784.8% above this industry median. Based on the distribution chart, Gubra AS ranks #2 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #2 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Gubra AS in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Gubra AS's value of 428.40% is 2784.8% above this benchmark. Historically, Gubra AS's own 3-Year EBITDA Growth Rate has ranged from 428.40 to 428.40 over the past decade. While the company's 10-year median is 428.40 vs. the industry median of 14.85, Gubra AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current 3-Year EBITDA Growth Rate of 428.40% is 2784.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gubra AS and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current 3-Year EBITDA Growth Rate is 428.40%, which is near median its own 10-year median of 428.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €386.89, compared to a current price of €52.15 — trading 86.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 428.40%, which is near median its 10-year median of 428.40 and 2784.8% above the Biotechnology industry median of 14.85. Gubra AS's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current 3-Year EBITDA Growth Rate is 428.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €52.15 is trading 86.5% below its estimated GF Value™ of €386.89.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
3-Year EBITDA Growth Rate: 428.40% (near median its 10-year median of 428.40)
GF Value™: €386.89 vs. price of €52.15 (86.5% below fair value)
Industry Position: 2784.8% above the Biotechnology median (#2 of 1136)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
75GF Score
Get the complete analysis for FRA:PI3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
